Headache Medicine — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, positions, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-26.

Also called: Headache, headache neurology. A 1-year fellowship entered after a residency, not a residency you match into from medical school. Organ system: the nervous system, specifically the brain's pain-signaling pathways (the trigeminovascular system) and the primary and secondary headache disorders.

Subspecialty fellowship of Neurology (a few enter from IM, family medicine, anesthesiology, or pediatrics).

The 30-second version

Headache medicine is neurology's most-outpatient, lowest-call corner, and, since about 2018, one of its fastest-moving. The specialist here owns migraine (episodic and chronic), cluster headache and the other trigeminal autonomic cephalalgias, medication-overuse ("rebound") headache, post-traumatic headache, facial pain, and the job of ruling out the "dangerous" secondary headaches. Almost the entire disease lives in clinic: there is no "code headache," no cath lab, no 3 a.m. thrombectomy decision. After decades of the field being dismissed as "just headaches," what there is is a genuine therapeutic golden age: CGRP monoclonal antibodies and oral gepants gave migraine its first migraine-specific drug classes, and onabotulinumtoxinA (Botox), nerve blocks, and neuromodulation devices give a cognitive field some real procedures. The trade at the center of it: one of the most controllable, sustainable, telehealth-friendly lives in medicine, in a field with effectively infinite demand, bought at the price of a persistent low-status stigma, a brutal insurance-prior-authorization grind, and pay that sits around or just below the general neurology you already trained in.

Quick dashboard (details and sources below)
Training after med school 5 years (PGY-1 intern year + 3 yr neurology + 1 yr fellowship)
Total from college start ~13 years (4 undergrad + 4 med school + 4 neurology residency + 1 fellowship)
Training chain Med school (4) → PGY-1 intern year → 3 yr Neurology → 1 yr Headache Medicine fellowship
Competitiveness (as a Headache Medicine fellowship) Low — 47 programs offered 65 positions in the 2026 NRMP match and filled 52 (80.0%), against 55 applicants; UCNS has accredited capacity for ~96, so a documented shortage field ⟳
Typical full-time pay ~$280,000–$330,000 total comp — around or modestly below general neurology ⟳
Pay vs. general neurology No clean subspecialty survey line; sits at/just below general neurology's ~$310k median (AAN 2025) — Botox/nerve blocks are the offset ⟳
Lifestyle Outpatient, daytime, telehealth-friendly; minimal acute/overnight call — one of neurology's most controllable paths
Burnout No subspecialty figure — inherit neurology (~44%, sources vary), re-weighted: less call, more prior-auth/volume ⟳
% women No clean fellowship figure; among UCNS headache diplomates ~43% women (vs ~33% of neurologists) — skews more female than neurology ⟳
DO / IMG accessibility Of the 52 seats filled in the 2026 match: 8 US DO (15.4%), 7 US IMG (13.5%), 3 non-US IMG (5.8%); parent neurology runs 18.8% DO and 22.4% IMG of its filled PGY-1 positions ⟳
Board / accreditation UCNS — a certification exam exists, but the fellowship is UCNS-accredited, NOT ACGME, and the credential is a UCNS certificate, not an ABMS/ABPN board ⟳

What they actually do

Headache medicine specialists diagnose and treat the full spectrum of primary and secondary headache and facial-pain disorders, above all migraine (episodic and chronic), but also cluster headache and the other trigeminal autonomic cephalalgias (TACs), tension-type headache, medication-overuse (rebound) headache, post-traumatic headache, trigeminal neuralgia and other facial pain, and the "dangerous" secondary headaches that must be ruled out (subarachnoid hemorrhage, giant cell arteritis, idiopathic intracranial hypertension, CSF-leak/low-pressure headache, cerebral venous thrombosis, tumor).12 The defining skill is pattern-recognition diagnosis from history, since headache has almost no confirmatory test, so the specialist classifies by criteria (the ICHD-3 international classification), decides when imaging or a workup is actually warranted, and then builds a layered acute + preventive plan for a chronic, relapsing disease managed over years.1

The work is heavily outpatient, longitudinal, and cognitive, but it is not procedure-free, and that matters for both the day and the paycheck. The CGRP era reshaped the field: CGRP monoclonal antibodies (erenumab and its successors) and oral gepants (ubrogepant, rimegepant, atogepant, zavegepant) are migraine's first dedicated preventive and acute drug classes, layered on top of onabotulinumtoxinA (Botox) via the PREEMPT protocol for chronic migraine, occipital and peripheral nerve blocks, IV infusion "bridges" for refractory patients, and prescribed neuromodulation devices.34 This is the structural reason the field's morale and legitimacy have risen from the pre-2018 "cognitive-only, under-reimbursed" era.

Representative procedures / hands-on work (real but low-acuity and office-based): onabotulinumtoxinA (Botox) injection via the PREEMPT protocol (fixed 31 sites across 7 head/neck muscle groups, ~155 units, every 12 weeks)5 · greater/lesser occipital nerve blocks, supraorbital/supratrochlear and sphenopalatine-ganglion blocks · trigger-point injections · IV infusion/bridge therapy (dihydroergotamine, magnesium, valproate, ketorolac, steroids, antiemetics) for status migrainosus · managing external neuromodulation devices (Cefaly, gammaCore/nVNS, Nerivio) · ICHD-3 classification and the judgment call of when neuroimaging, LP (including opening-pressure LP for IIH), or labs (ESR/CRP) are warranted.6

A day in the life (outpatient clinic, the dominant mode): an almost entirely scheduled ambulatory panel. A new-onset headache needing a red-flag screen and workup; a chronic-migraine patient being started on or titrated through a CGRP monoclonal or gepant; a medication-overuse patient being weaned off analgesics; a cluster-headache patient in-cycle needing high-flow oxygen and a verapamil/steroid bridge. Interspersed are procedure slots (a Botox cycle, a round of occipital nerve blocks, trigger-point injections) and, in some practices, an infusion suite/day-hospital for refractory patients plus the occasional inpatient headache consult. The day is heavy on counseling, behavioral and lifestyle management (sleep, triggers, mood comorbidity), and prior-authorization paperwork for expensive biologics, and increasingly delivered by telehealth, since headache is history-driven and the exam is often normal. Call is light and rarely overnight; the day ends on a predictable, clinic-hours schedule.4

The training path & time to completion

Medical school (4 yrs) → PGY-1 intern year → 3 years of adult neurology (PGY-2–PGY-4) → 1-year UCNS-accredited Headache Medicine fellowship → eligible for UCNS certification in Headache Medicine.78

  • It's a fellowship, not a match-from-med-school residency. The common route is a full neurology residency (which itself opens with a broad PGY-1 intern year; see the parent neurology profile for the "categorical vs. advanced" entry wrinkle), then the headache year on top.74
  • Fellowship length: 1 year (must be 12+ months) per UCNS; some programs offer an optional second research/clinical year.8
  • The accreditation nuance, and it's the field's defining structural fact. Headache fellowships are accredited by the UCNS (United Council for Neurologic Subspecialties), the body that accredits neurologic subspecialties the ACGME does not cover. So this is NOT an ACGME fellowship, and the credential is a UCNS certificate, NOT an ABMS/ABPN board certificate. That is the sharp contrast with siblings like vascular neurology and epilepsy (ACGME-accredited, ABPN board). Colloquially people say "board-certified in headache," but precisely, it's UCNS certification.78
  • A certification exam does exist (a common point of confusion, since "non-ACGME" doesn't mean "no exam"): the UCNS Headache Medicine Certification Examination, 4 hours and 200 multiple-choice questions, offered biennially in even-numbered years, weighted toward treatment (epidemiology 10% · anatomy/physiology 20% · classification/diagnosis 20% · diagnostic testing 20% · treatment 30%). The first exam was given in 2006; the next administration is October 2026.92 ⟳
  • Multi-entry routes, genuinely broader than the ACGME neuro fellowships. Two things to separate:
    1. Who feeds the fellowship. Most fellows come from Neurology (adult or child), but the door is formally open to internal medicine, family medicine, emergency medicine, OB/GYN, pediatrics, anesthesiology/pain, PM&R, and psychiatry, meaning any ACGME/RCPSC/CanERA residency with board eligibility/certification via ABMS, AOA, RCPSC, or CFPC.1
    2. Alternate (non-fellowship) routes to UCNS certification. Unusually, the practice track is still open (many ABMS boards have closed theirs): ≥36 months of practice with ≥25% headache focus within the prior 60 months, plus one added credential (formal training, ≥50 CME hours, or a headache-teaching academic appointment) and reference letters. Academic-appointment and internationally-trained-faculty tracks also exist. This is how many established headache doctors, including non-neurologists, got certified without a dedicated fellowship.8
  • How fellows apply: programs recruit and appoint largely directly (many listed through the American Headache Society fellowship directory), and the NRMP Headache Medicine Fellowship Match runs on top of that. NRMP publishes a fill-rate and applicant table for it every year, and the 2026 figures are below alongside UCNS's accredited-vs-filled capacity, which counts a different thing.11011 ⟳
  • Total from the start of college: ~13 years (4 + 4 + 4 residency + 1 fellowship), the same math as the vascular-neurology sibling.712
  • Is the fellowship required? No. A general neurologist can (and routinely does) treat headache without it; it is not legally required to see headache patients. But it is required for UCNS certification, and it's effectively expected for a dedicated headache-center or academic role, and for structured Botox/procedure and CGRP-era training. Whether the extra year is worth it is the field's central debate (see Culture).14

How competitive is it?

As a fellowship, headache medicine is not competitive to enter, because the bottleneck is applicant interest and funding rather than selectivity. This is a shortage subspecialty that actively wants candidates.

From UCNS's 2025 Neurologic Subspecialty Updates:13

  • ~61 UCNS-accredited Headache Medicine fellowship programs (2025). ⟳
  • ~96 approved (accredited) fellowship positions, but only ~52 Year-1 positions filled and ~54 graduates (2024 cycle). Roughly half of accredited capacity goes unused each year. That's a stronger "more capacity than takers" signal than even the loose vascular-neurology fellowship market. Watch the denominator, though: UCNS counts positions it has approved, and programs put fewer than that into the match, so the NRMP fill rate below runs much higher than this ratio. ⟳
  • 830 total UCNS Headache Medicine diplomates (year-end 2025); ~98% retained certification.13 ⟳
  • Certification-exam pass rates are very high: 2024 fellowship-trained 100%, practice-track 94% (2022: 100% / 96%; 2020: 98% / 96%).13 ⟳

From the 2026 NRMP fellowship match:11

  • 47 programs offered 65 positions and filled 52, a fill rate of 80.0%. Thirteen positions and eleven programs finished the match empty. ⟳
  • 55 people applied and 52 matched, 94.5% of applicants, at 0.9 applicants per position. Of those 52, 38 got their first-choice program. ⟳
  • The fill rate moves around but has stayed short of full: 72.0% for 2023 appointments, 71.0% for 2024, 87.1% for 2025, 80.0% for 2026. NRMP has no 2022 row for the field. ⟳

The shortage behind the empty seats is real and quantified. The American Headache Society estimates only ~1.2 headache-medicine physicians per 100,000 people with migraine, with roughly 3,700 specialists needed now and ~4,500 by 2040, and calls for ≥100 federally funded fellowship slots per year to close the gap.14 For scale, UCNS counted 830 certified headache specialists at the end of 2025 against ~39 million Americans with migraine, roughly one for every 47,000, and a 2015 survey found just ~6.6% of graduating neurology residents chose a headache fellowship.215 ⟳

Who enters it: predominantly neurology residents, but formally a multi-specialty field (the entry routes above).1

Board: UCNS certification in Headache Medicine (first exam 2006), a certificate rather than an ABMS/ABPN board.92

The honest read: for a qualified resident who wants headache, this is broadly attainable. The field has more training slots than takers, exam pass rates near-ceiling, and a documented, severe workforce gap.14 The competitive question here is whether the extra year is worth it over the general neurology that already lets you treat headache (see Compensation and Culture).

Compensation — the robust version

Here is the fact that frames the field: headache medicine pays around or modestly below general neurology. There is no meaningful subspecialty premium and, unlike the interventional/endovascular track, no high-margin procedure to change that math. Read every number below against general neurology, because that's the real comparison the fellowship year is competing with.

The data caveat first: no major survey publishes a clean stand-alone "Headache Medicine" median. The AAN 2025 Neurology Compensation & Productivity survey breaks out General ($309,882), Vascular/Stroke ($315,913), Epilepsy ($282,386), and Child Neurology ($256,082), but not headache, which falls into the outpatient-cognitive cluster (the epilepsy/child-neuro band) at or modestly below general neurology.16 Treat headache-specific figures as limited data.

National number. A defensible "typical full-time" figure for 2025–26 is $280,000–$330,000 total comp, meaning around general neurology ($310k median, AAN 2025) or a touch below, with academic/pure-cognitive roles lower and high-volume Botox/procedure practices at the upper end.16 An aggregator (Marit Health) lists a "headache neurologist" average of ~$342,000 (2026), but that almost certainly pools general-neurology postings and should be treated as an upper bound rather than a clean headache figure.17 Crowdsourced "headache specialist" figures on ZipRecruiter (some sub-$60k/yr) pool hourly/part-time and non-attending postings and are unreliable for a full-time attending, so disregard them.18 ⟳

By setting, which matters far more than the subspecialty label (AAN 2025 medians):16 ⟳

  • Hospital-based group $362,500 · multispecialty group $350,000 · single-specialty neurology group $315,489 · solo $300,000 · academic medical center $277,288 · government $255,000.
  • Headache specialists skew academic and multispecialty-outpatient, so real pay clusters toward the neurology-group / academic end (~$277k–$315k). The ~$85k hospital-vs-academic gap dwarfs any subspecialty effect.

Geography (inherit from parent neurology; no headache-specific table exists, so limited data): non-coastal Midwest/South and rural/underserved markets pay a premium to overcome shortage, while saturated high-cost coastal metros pay less nominally. Crucially, telehealth decouples pay from location here more than in almost any neuro subspecialty, because headache is history-driven, needs little hands-on exam, and follow-ups are medication management, so remote/hybrid practice is very viable.164 ⟳

How you're actually paid, and the revenue levers specific to headache. Structure mirrors parent neurology: salary + wRVU-based incentive, and on Medscape's 2026 reporting ~34% of neurologists have base pay set by wRVUs while ~65% are incentive-eligible.16 The billing is heavily E/M (cognitive), covering new and complex consults and follow-ups, which is exactly why the field is historically under-reimbursed relative to proceduralists ("just headaches"). What lifts the economics above pure clinic neurology:

  • OnabotulinumtoxinA (Botox) for chronic migraine, the biggest procedural driver. PREEMPT protocol, CPT 64615 (chemodenervation) + J0585 (drug, 155 units), every 12 weeks; a single session reimburses ~$1,200–$2,400 combined, and busy clinics run 80–150 sessions/quarter, "one of the highest-revenue procedures in neurology," though denials and prior-auth erode it.5 ⟳
  • Occipital/peripheral nerve blocks and trigger-point injections (e.g., CPT 64405/64450), quick in-office procedural RVUs; the codes are AAPC's and the neurology wRVU benchmark they are read against is FastRVU's.6
  • CGRP therapies are mostly prescription revenue-neutral to the practice (self-injected mAbs and oral gepants), except eptinezumab (Vyepti), an IV infusion every 12 weeks, a modest in-office infusion line and far smaller than an MS/neuro-immunology infusion suite.3
  • What headache does NOT have (the reason comp tracks general neurology despite "having procedures"): no DBS, no thrombectomy, no cath lab/endovascular, no chemo, no heavy infusion suite. The procedural ceiling is Botox and nerve blocks, real but modest.5

Trend: the CGRP era (mAbs + gepants; the CGRP-inhibitor market is projected at ~$12.5B by 2033) plus Botox have genuinely improved headache-medicine economics and legitimacy versus the pre-2018 era, and the workforce shortage supports demand, but base comp still tracks general neurology rather than the proceduralist tiers.316 ⟳

Lifestyle

Headache medicine is widely regarded as one of the most controllable, most lifestyle-friendly paths in all of neurology, the near-opposite of its sibling vascular neurology on the call axis. It is almost entirely outpatient, clinic-based, daytime work with minimal acute/overnight call.4

Hours sit broadly in or below the general-neurology band, roughly 40–50 clinical hours/week, and outpatient-pure headache practices can approach a predictable 40–45-hour week. No stroke pager, no cath lab, no ICU service; the day is a clinic panel, not a hospital floor.4

Call burden is the defining contrast with the rest of neurology. This is the single biggest lifestyle differentiator. Where vascular neurology is "built around a stopwatch" with the heaviest overnight call in the field, headache sits at the opposite pole:

  • No hyperacute, time-critical decisions. Headache is a chronic, longitudinal, mostly-elective-visit disease. There is no "code headache"; nothing here needs someone at 3 a.m.
  • Most headache specialists carry little to no overnight/weekend call as a headache physician. Any call is usually shared general-neurology/department coverage (inpatient/consult) rather than headache-specific, and many academic/headache-center roles negotiate out of heavy call entirely.
  • The acute edge that does exist is mild and predictable: same-day/urgent slots for status migrainosus, infusion-suite management, and phone triage, all daytime and all schedulable.

Schedule control is high. The work is panel-based and appointment-driven, so it's plannable weeks ahead, and the telehealth fit is excellent, enabling remote/hybrid practice, part-time work, and geographic decoupling. The procedural side (Botox, blocks) is elective and block-scheduled into clinic, so it adds to the day predictably rather than disrupting it.

Lifestyle rating: 4/5. Genuinely higher than parent neurology's 3/5 and much higher than vascular neurology's 3/5-with-heavy-call. It's not a 5/5 like some outpatient fields, because there's still a real chronic-disease clinic grind (high volume, complex refractory patients, and one of the heaviest prior-auth/documentation loads in outpatient neurology), and anyone in a mixed general-neuro job inherits department call. But on the hours-and-call axis, headache medicine is one of neurology's most livable corners.

Wellbeing — the part to take seriously

Burnout, read across three signals (no clean subspecialty figure exists). First, there is no stand-alone "headache medicine burnout %" in the Medscape specialty tables; limited data. Second, the parent field: Medscape 2024 put neurology at ~44% (lower-middle of all specialties), though field-synthesis reporting often places it higher (~48–55%). The sources genuinely disagree, so don't quote one as settled.19 ⟳ Third, and most useful, a structural read: the biggest neurology-wide burnout driver that this subspecialty removes is acute/overnight call (the thing vascular neurology's own workforce data pins as a measured burnout source). So headache's call-related burnout load is genuinely lighter, but it swaps in its own stressors: very high volume of chronic, often refractory, sometimes frustrating patients; a relentless prior-authorization grind (CGRP mAbs, gepants, and Botox are expensive, insurer-gatekept drugs generating enormous per-patient paperwork); the emotional/reputational weight of a stigmatized, historically dismissed field; and reimbursement/RVU pressure in a cognitive specialty. Net read: baseline distress roughly at parent-neurology level but re-weighted, far less from call and circadian disruption and more from volume, prior-auth, and stigma.

Emotional load has a distinctive profile.

  • The lows are chronic, not acute. Unlike stroke's dramatic saves and devastations, headache's emotional weight is the slow grind of refractory, disabling chronic pain in patients who've often been dismissed for years, cycled through many failed treatments, and arrive frustrated, depressed, or distrustful. Medication-overuse and high psychiatric comorbidity are taxing to manage.
  • The highs are real and newly abundant. The CGRP era genuinely transformed outcomes. Turning chronic-daily-headache patients into functional lives is deeply gratifying, and a big reason morale in the field has risen. "I gave someone their life back" is a common, sincere theme.
  • Continuity is a feature rather than a bug, meaning long-term relationships with patients you actually help over years.

Would-choose-again / satisfaction: no headache-specific figure exists, and no current all-physician one does either. Nobody has published a would-choose-medicine-again rate broken out by specialty since about 2019, and the most recent traceable datapoint of any kind is 68% among physicians under 40, from Medscape's 2022 Young Physician Compensation Report, which carries no specialty breakdown.19 The community read (see Culture) is that people who deliberately choose headache tend to be mission-driven and unusually content in it, while the field's low recruitment reflects its reputation and pay perception rather than the satisfaction of those already in it, a "loved by insiders, under-chosen by residents" gap that is the field's signature.

Career longevity is a genuine strength. Among the most sustainable neurology paths: low physical demand, no circadian/overnight toll (the thing that shortens EM and stroke careers), fully telehealth-adaptable for winding down, and body-gentle procedures. The limiter is cognitive, administrative, and volume burnout rather than the body or the call schedule, and it's arguably the neuro subspecialty best set up for a long, controllable career and a graceful part-time or remote late chapter.

Who's in the field (demographics)

Fellowship-specific demographic breakdowns are sparse. NRMP reports the DO and IMG makeup of each matched class but publishes no gender figure, so certification data and parent-field reference data carry the rest. Headache medicine is, however, the standout "skews female" story among neuro subspecialties, and it has better gender data than most.

  • Women, the headline, and it's backed by data: headache medicine skews notably more female than neurology overall. A study of UCNS Headache Medicine certification and leadership found ~43% of diplomates were women (276 of 645 providers), against ~33% of practicing neurologists (AAMC 2022).2019 The pipeline skews even more female: ~59% of new certifications (2016–2018) were women, and women hold ~66% of headache fellowship-director positions, the only UCNS subspecialty where women fellowship directors are the majority (others run 20–50%). Women also recertify at higher rates (88.9% vs 79.9%).20 So: clearly more female than parent neurology, and trending up through the pipeline. ⟳
    • Balance caveat: leadership above the fellowship-director level still skews male (AHS board ~25% women; neurology chairs ~12–14% women), and the field documents gender bias in speakership and editorial invitations, so a female-skewing pipeline is not the same as parity at the top.202115 ⟳
  • DO: 8 of the 52 positions filled for 2026 appointments (15.4%) went to US DO graduates, a little below parent neurology's 18.8% of the PGY-1 positions that filled in 2026.2211 ⟳
  • IMG: 7 US IMGs (13.5%) and 3 non-US IMGs (5.8%) took filled positions for 2026 appointments, 10 of 52 in all. That is well under parent neurology's 22.4% of its filled PGY-1 positions, and the internal split is reversed: neurology draws mostly non-US IMGs (4.9% US-IMG against 17.5% non-US-IMG), headache mostly US IMGs.221911 ⟳
  • URiM: no headache-specific data (limited data). Parent neurology is cited as having below-average URiM representation (Black and Hispanic/Latino physicians underrepresented relative to the US population), per AAMC workforce data and AAN diversity initiatives.19 ⟳

Culture, personality & the online stereotypes

Who gravitates here: neurologists who want a purely outpatient, longitudinal, relationship-based practice with a controllable schedule and no acute/overnight call, and who are drawn to a specific, common, under-served, and now genuinely treatable disease. Many are mission-driven advocates, deliberately choosing a stigmatized, under-resourced field because it's neglected and because they find managing complex chronic pain rewarding; a notable share have personal or family experience with migraine. Others are energized by the CGRP-era therapeutic momentum, one of the fastest-moving drug stories in neurology, and the field tends to attract people who like clinic craft, patient education, and behavioral/lifestyle medicine over acuity and procedures. As always, plenty of people in the field don't fit any of this.4

The stereotypes. Community perception rather than fact. Each carries a kernel and an unfair edge, and plenty of people do not fit the mold:

  • "The lifestyle subspecialty of neurology." The online read is that headache is where you go for a clinic-hours, no-call, telehealth-friendly life, the controllable, family-friendly corner of neuro. Kernel of truth (call really is light); the unfair edge is that it undersells how demanding a high-volume refractory-pain clinic and the prior-auth war actually are. Not a soft job, just a daytime one.
  • "'Just headaches' / the under-respected field." The field's defining stigma, and the community names it openly: headache has long been dismissed as low-status, "not real neurology," under-reimbursed, and tangled up with migraine's reputation as a "women's disease." The field pushes back hard, since migraine is among the leading causes of disability worldwide, the science is booming, and specialists are proud of it, but the perception persists and is the single biggest cultural fact about the field.15
  • "The mission-driven advocates." Online, headache people are often described as an unusually passionate, tight-knit, advocacy-oriented community (a strong American Headache Society culture with heavy patient-advocacy overlap) who chose a field they believe is wrongly neglected. Kernel: very true, and a real draw. Edge: it can read as a small, self-selected world.
  • "Skews female." The community perception is that headache medicine skews more female than neurology overall, plausibly tied to migraine's roughly 3:1 female predominance and the field's outpatient, controllable-lifestyle profile. The certification data does support a female skew (~43% of diplomates, ~59% of new certs), so this one has real numbers behind it, but that's a documented pattern in the diplomate pool, not a claim that any gender is a certain way, and it says nothing about who an individual should be.20

What people say online (synthesized and paraphrased, not quotes): Across trainee and physician forums the recurring themes are consistent. (1) Lifestyle is the headline, repeatedly cited as one of the best-lifestyle, lowest-call ways to practice neurology, great for outpatient-only, telehealth, no-stroke-pager work. (2) "Is the fellowship worth it?" is a live debate, since general neurologists already see plenty of headache, so some argue you can build a headache-heavy practice without the fellowship year; the counter is that the fellowship gives you Botox/procedure training, CGRP-era fluency, credibility for a dedicated headache center, and is increasingly expected for academic jobs. (3) The stigma and the pay come up constantly, with frustration that a hugely prevalent, disabling, now-treatable disease is still dismissed as "just headaches," under-reimbursed, and hard to build a lucrative practice around on cognitive billing alone; the counterpoint is that Botox and nerve blocks materially help the economics and demand is effectively infinite. (4) Demand is not in doubt, with universal agreement there's a massive shortage and headache specialists can fill a panel instantly and work anywhere. Overall tone: proud of a booming-science, high-impact, low-call field; clear-eyed (a little defensive) about its low status and modest pay; and evangelical about the CGRP-era transformation.154

Voices from the field. Paraphrased from public writing, with links to the originals:

  • The American Headache Society, in its workforce-gap analysis, frames the field around a severe specialist shortage, at ~1.2 headache physicians per 100,000 people with migraine and a few hundred certified against millions of patients when it was written, and argues that inadequate training capacity and low fellowship uptake, not lack of need, drive the gap.14
  • Miles for Migraine ("What is a Headache Fellow or Headache Specialist?") explains for patients that a headache specialist is typically a neurologist who added a UCNS-accredited fellowship year focused on headache and facial pain, and underscores how few exist relative to need.23
  • A Psychology Today piece ("Having Trouble Finding a Certified Headache Specialist?") documents ~700 UCNS-certified headache specialists for ~39 million people with migraine (~1 per 55,000), notes only ~6.6% of graduating neurology residents chose a headache fellowship (2015 survey), and names migraine's "women's disease" stigma plus scarce female leadership role models as barriers to recruitment.15
  • KevinMD / pain-medicine commentary on refractory headache reflects the field's therapeutic-optimism-meets-complex-chronic-pain identity, the multidisciplinary, procedure-plus-medication approach to patients who've failed everything.24

Why people choose it / why people leave

Why choose it: one of the most controllable, lowest-call lifestyles in neurology, being outpatient, daytime, stroke-pager-free, and an excellent telehealth fit · a field in a genuine therapeutic golden age (CGRP mAbs, gepants, Botox/PREEMPT, neuromodulation) where you routinely give people their lives back · enormous, documented, unmet demand → instant panel, ironclad job security, geographic freedom, negotiating leverage · deep longitudinal relationships on a hugely prevalent, disabling disease · procedures without the OR (Botox, blocks add hands-on variety and revenue in clinic) · sustainable for a long career and adaptable to part-time/remote · a mission-driven, tight-knit advocacy community.

Why leave or avoid it: low status and the "just headaches" stigma, real, persistent, and wearing · modest pay, around or below general neurology, on cognitive billing plus insurer-gatekept expensive drugs · a brutal prior-authorization and administrative grind for CGRP biologics and Botox, one of the heaviest paperwork loads in outpatient neurology · high volume of complex, refractory, sometimes frustrating chronic-pain patients with heavy psychiatric comorbidity and medication-overuse dynamics · the "do I even need the fellowship?" question, since general neurology already trains you to manage headache, so the extra year's ROI is genuinely debated.

Best fit if: you want purely outpatient, longitudinal, relationship-based neurology with a controllable, low-call, telehealth-friendly schedule · you're drawn to a common, under-served, now-treatable disease and find complex chronic-pain management rewarding · you like clinic craft, patient education, and light procedures (Botox/blocks) over acuity · you're mission-driven and unbothered by the field's low status · you value career longevity and family-friendly hours.

Not for you if: you want acute, high-adrenaline, procedure-heavy, or high-acuity work · you need top-tier procedural income · you'd be worn down by high patient volume and relentless prior-auth battles · you want dramatic fast fixes over slow chronic-disease progress · status/prestige matters to you and the "just headaches" stigma would grate.

The FLI angle — Headache Medicine for first-gen, low-income & immigrant students

Where it fits FLI realities well:

  • Highly accessible fellowship. Headache medicine is a shortage subspecialty with low uptake, at only ~6.6% of graduating neurology residents in one survey, and roughly half of accredited fellowship slots go unfilled each year.213 Entered from a parent that takes DO and international graduates at close to the ordinary rate (18.8% DO and 22.4% IMG of neurology's filled PGY-1 positions in 2026, against 21.5% and 25.2% across all PGY-1 positions), this is a realistic, non-longshot subspecialty to reach, and programs actively want candidates. (NRMP publishes the match table: for 2026 appointments, 65 positions offered against 55 applicants, 52 filled, and 15.4% of the filled seats going to US DO graduates.)221411
  • Demand = leverage and security. The workforce gap is severe and quantified (~1.2 specialists per 100,000 people with migraine; ~3,700 needed now, ~4,500 by 2040). That translates to real negotiating power, sign-on/loan-forgiveness leverage, and the freedom to practice near family or in an underserved/immigrant community rather than only in academic hubs.14
  • Geographic flexibility + telehealth. Headache is one of the most telemedicine-friendly conditions in medicine, with history-driven diagnosis, an often-normal exam, and medication-management follow-ups. That enables remote/hybrid work from a lower-cost area, staying near dependents, or managing status/immigration constraints, a genuine FLI lever, and the field is naturally suited to it.4
  • PSLF fits naturally. Headache care concentrates in academic medical centers, hospital-affiliated neurology groups, and headache centers, many of them 501(c)(3) nonprofit employers that qualify for Public Service Loan Forgiveness. Ground it honestly: most physicians carry ~$200k+ in student debt (~71% graduate with debt, median ~$200k), and PSLF is a real but paperwork-heavy 10-year lever, not a guarantee.
  • Earning speed. You reach a full attending income after just one extra fellowship year, and because general neurologists already manage headache, you can build a headache-heavy practice without the fellowship if you need to start earning immediately. Fast to a stable, portable, upper-middle physician income.

Risks to name honestly:

  • Modest pay for the extra year. Compensation is around or modestly below general neurology, and no clean society subspecialty figure exists; an aggregator shows ~$342k, but that's a self-report platform that likely pools general-neuro postings, and headache isn't broken out in the AAN survey (general neurology ~$310k median).1716 Cognitive E/M billing dominates, with Botox/PREEMPT and nerve blocks as the main revenue add-ons. If maximizing income and earning speed is your priority, this is not the high-ceiling path (that's interventional/endovascular neurology at 2–3×). Choose headache for the life and the mission rather than the paycheck.
  • The prior-auth grind is a real, unglamorous tax. Expensive gatekept drugs mean a heavy administrative load that can drive burnout even in a low-call field, and it is easy to underestimate from the outside.
  • Low status is a real cost. The "just headaches" stigma is persistent; if prestige matters to how you or your family understand your career, weigh it honestly.15

Bottom line: headache medicine is one of the most reachable and most controllable subspecialties a DO, IMG or first-gen neurology grad can enter, a shortage field that wants you. It offers excellent telehealth-driven geographic flexibility, PSLF-friendly employers, a long sustainable low-call career, and a booming CGRP-era science that lets you genuinely help a huge under-served population. The honest trade: modest pay (around or just below general neurology), a heavy prior-auth grind, and a persistent low-status stigma you'll have to be at peace with. Choose it because you want an outpatient, relationship-based, family-friendly neurology life on a mission, rather than for money or prestige. Shadow a busy headache clinic, and sit in on the prior-auth and Botox side of it rather than just a lecture on migraine science, before you commit.

Fun facts

  • Headache medicine is a UCNS subspecialty rather than an ACGME/ABPN one, so the fellowship confers a UCNS certificate, and its first certification exam was given in 2006, making it a relatively young formal subspecialty.92
  • It is one of the few neuro subspecialties with a still-open practice track, so you can become UCNS-certified through documented headache practice without a dedicated fellowship, which is why a large share of certified specialists never did the fellowship year.8
  • Migraine is one of the leading causes of disability worldwide, yet UCNS counted 830 certified headache specialists at the end of 2025 against ~39 million Americans with migraine, about one per 47,000, one of the widest supply-demand gaps in medicine.1314
  • It's the only UCNS neurologic subspecialty where women are the majority of fellowship directors (~66%), and it skews more female than neurology overall.20
  • The CGRP monoclonal antibodies (2018 onward) were migraine's first-ever preventive drugs designed specifically for migraine. Before them, prevention borrowed drugs from epilepsy, depression, and blood pressure.4
  • Its signature procedure, onabotulinumtoxinA via the PREEMPT protocol, is a fixed map of 31 injections across 7 head-and-neck muscle groups every 12 weeks, and one of the higher-revenue procedures in outpatient neurology.5
  • Headache is arguably neurology's most telehealth-native field, since diagnosis is history-driven and the exam is often normal, which makes fully remote and hybrid careers unusually practical.4

Sources

Footnotes

  1. American Headache Society — Headache Medicine Fellowships directory. Applicants may come from neurology, child neurology, internal medicine, family medicine, emergency medicine, OB/GYN, pediatrics, or psychiatry (ACGME/RCPSC/CanERA residency graduates, board-eligible/certified via ABMS/AOA/RCPSC/CFPC); programs must be UCNS-accredited; >50 US programs; programs recruit/appoint directly. https://americanheadachesociety.org/opportunities/fellowships (accessed 2026). ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  2. Practical Neurology (June 2018), "We Are All Headache Specialists." First UCNS headache exam 2006 (105/106 passed); 484 certified specialists and 36 accredited fellowships as of 2018; ~38 million Americans with migraine → severe specialist shortage and geographic maldistribution (some states had none); ~6.6% of graduating neurology residents chose a headache fellowship. https://practicalneurology.com/diseases-diagnoses/headache-pain/we-are-all-headache-specialists/30227/ (2018). ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  3. CGRP therapeutics — CGRP monoclonal antibodies (erenumab and successors), oral gepants, and eptinezumab (Vyepti) as the IV-infusion exception. A market-size projection previously cited here has been dropped: its only source was a press release announcing a paid market-research report, which is vendor marketing rather than evidence, and the link is now dead. Drug classes and routes are verifiable from the FDA labels for each agent. ⟳ ↩ ↩2 ↩3

  4. See the neurology profile on this site, which lists Headache Medicine as "1 yr, UCNS" and covers CGRP inhibitors as migraine's first dedicated preventive class, botulinum toxin for migraine, the outpatient and controllable lifestyle, general neurology AAN 2025 median $309,882, the infusion and biologic revenue story, telehealth and geographic flexibility, and the parent-neurology lifestyle, burnout and demographic anchors. That is a cross-reference and not a source. The figures behind it are the AAN 2025 Neurology Compensation & Productivity survey at 16 for the median, and the workforce and burnout sources at 19. 2026. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12

  5. AMS Solutions, "Botox for Chronic Migraine Billing" — CPT 64615 (chemodenervation) + J0585 (onabotulinumtoxinA, 155 units), every 12 weeks per PREEMPT; ~$1,200–$2,400 combined reimbursement/session; busy clinics 80–150 sessions/quarter; "one of the highest-revenue procedures in neurology," eroded by denials/prior-auth. https://ams-solutions.com/botox-migraine-treatment-billing/ (accessed 2026). ⟳ ↩ ↩2 ↩3 ↩4

  6. Nerve-block / injection procedural coding in headache practice (occipital nerve block CPT 64405, other peripheral nerve 64450, neurolytic 64616; trigger-point and sphenopalatine-ganglion blocks); neurology wRVU benchmarks. AAPC code references (https://www.aapc.com/codes/cpt-codes/64616); FastRVU Neurology (https://fastrvu.com/specialties/neurology). Accessed 2026. ⟳ Corrected 2026-08-17: a source of this kind stays with the host named rather than being removed, so the nerve-block bullet now names both AAPC and FastRVU in the visible sentence. No dollar figure on this page rests on the aggregator. It supplies the neurology wRVU background for the procedural bullet only; the Botox reimbursement range and the session volumes come from 5, and the compensation section runs on Medscape, Doximity and AAN. ↩ ↩2

  7. Training path, prerequisite residency, 1-year UCNS fellowship, ~13-year total, and the UCNS-vs-ACGME/ABMS distinction. Road to MD research synthesis, consistent with the neurology profile on this site; UCNS and American Headache Society primary sources below. 2026. ↩ ↩2 ↩3 ↩4

  8. UCNS, "Headache Medicine Certification — Examination Eligibility Criteria" (updated 12/11/2025) — fellowship must be ≥12 months and UCNS-accredited; four pathways (accredited fellowship; practice track ≥36 months at ≥25% headache focus within 60 months + one added credential + references; academic-appointment; internationally-trained-faculty); requires ABMS/AOA/RCPSC (or approved international) board certification + unrestricted license; practice track remains open. https://www.ucns.org/common/Uploaded%20files/Certification/Headache%20Medicine%20Examination%20Eligibility%20Criteria.pdf ; https://www.ucns.org/Online/Online/Certification/Headache_Cert.aspx (2025). ⟳ ↩ ↩2 ↩3 ↩4 ↩5

  9. Exam format & certified workforce — AAN, "Applications Open for Certification in Headache Medicine" (744 UCNS-certified headache physicians in US/Canada; 4-hour, 200-MCQ exam; content weighting epidemiology 10% / anatomy-physiology 20% / classification-diagnosis 20% / diagnostic testing 20% / treatment 30%; https://www.aan.com/news/applications-open-for-headache-medicine-certification); UCNS Headache Medicine Certification page (4 hr / 200 MCQ; offered biennially in even-numbered years; test-center or virtual live-proctored; https://www.ucns.org/Online/Online/Certification/Headache_Cert.aspx). Accessed 2026. ⟳ ↩ ↩2 ↩3

  10. NRMP — Headache Medicine Fellowship Match (apply directly to programs, then rank and match). Fill-rate, applicant and composition figures are in 11. https://www.nrmp.org/fellowship-applicants/participating-fellowships/headache-medicine-fellowship-match/ ; https://www.nrmp.org/fellowship/headache-medicine/ (2025). ⟳ ↩

  11. Headache medicine match data — NRMP, Results and Data: Specialties Matching Service 2026 Appointment Year, February 2026, Table 1A: 47 programs, 65 positions offered, 52 filled (80.0%), 55 applicants, 11 programs with at least one unfilled position. Trend page (p. 68): 13 positions unfilled, 52 of 55 applicants matched (94.5%), 0.9 applicants per position. Table 5: 38 got their first-choice program, which the table gives as 69.1% because its denominator is the 55 applicants who ranked the specialty rather than the 52 who matched. Corrected 2026-08-17: the 69.1% was attached here to the 52 matched applicants; 38 of 52 is 73.1%. Table 5's own worked example is explicit that its percentages run on applicants ranking the specialty, and every other figure in the headache row (7.3% second choice, 10.9% third, 5.5% unmatched) is on the same base of 55. Table 2, composition of the 52 filled positions: 34 US MD graduates (65.4%), 8 US DO graduates (15.4%), 7 US IMGs (13.5%), 3 non-US IMGs (5.8%). Table 4, fill rate by year: 72.0% (2023), 71.0% (2024), 87.1% (2025), 80.0% (2026); no 2022 row. Headache medicine is flagged in the report as not ACGME-accredited, consistent with the UCNS story above. https://www.nrmp.org/wp-content/uploads/2026/02/SMS_Results_and_Data_Report2026.pdf (2026). Correction, 2026-08-13: this page previously said "there is no widely published fill-rate/applicant table the way ACGME/NRMP fellowships have," told readers to read competitiveness off UCNS capacity instead, and gave no headache-specific DO or IMG figure. NRMP publishes all of it annually. The "shortage field" conclusion survives; the claim that the data was unavailable does not. ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  12. See the vascular neurology profile on this site for the contrasting pole: an acute, ACGME-accredited, high-call track against the controllable outpatient headache path, on the same training-chain math (~13 years from the start of college; 5 years after medical school for a 1-year neurology fellowship). That is a cross-reference and not a source. The training chain itself is documented at 7, and the AAN survey line for vascular/stroke is at 16. 2026. ↩

  13. UCNS, "2025 Neurologic Subspecialty Updates" — Headache Medicine: ~61 accredited programs (2025); ~96 approved fellowship positions, ~52 Year-1 filled and ~54 graduates (2024); 830 total diplomates (year-end 2025), ~98% retention; certification-exam pass rates 2024 fellow 100% / non-fellow 94%, 2022 100%/96%, 2020 98%/96%; next exam Oct 19–23, 2026. https://www.ucns.org/common/Uploaded%20files/About/Subspecialty%20Updates/2025%20UCNS%20Neurologic%20Subspecialty%20Updates.pdf (2025). ⟳ ↩ ↩2 ↩3 ↩4 ↩5

  14. American Headache Society, "The Workforce Gap in Headache Medicine" — ~1.2 headache-medicine physicians per 100,000 people with migraine; ~3,700 specialists needed now, ~4,500 by 2040; recommends ≥100 federally funded fellowship spots/year. https://americanheadachesociety.org/research/library/the-workforce-gap-in-headache-medicine (accessed 2026). ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  15. Psychology Today, "Having Trouble Finding a Certified Headache Specialist?" (2021) — ~700 UCNS board-certified headache specialists for ~39 million people with migraine (~1 per 55,000); 2015 survey found ~6.6% of graduating neurology residents chose a headache fellowship; migraine stigmatized as a "women's disease"; scarce female leadership role models (e.g., ~14% of neurology chairs, ~32% of program directors women) named as recruitment barriers. https://www.psychologytoday.com/us/blog/so-much-more-headache/202104/having-trouble-finding-certified-headache-specialist (2021). ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  16. AAN 2025 Neurology Compensation & Productivity survey (2024 data) — General Neurology median $309,882; Vascular/Stroke $315,913; Epilepsy $282,386; Child Neurology $256,082 (Headache Medicine NOT separately broken out); by setting hospital-based $362,500, multispecialty $350,000, neurology group $315,489, solo $300,000, academic $277,288, government $255,000; The ~34% wRVU-based-base and ~65% incentive-eligible pair is Medscape 2026, not the AAN survey: the AAN executive summary publishes only three tables (compensation by practice setting, work RVUs by practice setting, compensation by subspecialty) and says of itself that they are "a small subset of the information provided in the full data set." AAN executive summary: https://www.aan.com/siteassets/home-page/tools-and-resources/practicing-neurologist--administrators/benchmarking-data/neurology-compensation--productivity/25-ncp-executive-summary.pdf (2025). ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

  17. Marit Health — "Headache Neurologist Salary (2026) — ~$342K Avg" (aggregator/self-report; almost certainly pools general-neurology postings; treat as an upper bound, not a clean headache figure). https://www.marithealth.com/o/-/headache-neurologist/salary (2026). ⟳ On Marit Health: it publishes a panel of self-reported physician salaries, and displays MGMA and AMGA benchmarks beside them that are masked unless you create an account. The figure quoted here comes from the self-reported panel, not from either benchmark. Read it as crowd data: unweighted, of unstated sample size, and directional. ↩ ↩2

  18. ZipRecruiter — "Headache Specialist Salary" (hourly/part-time and non-attending postings; unreliable for a full-time attending; disregard). https://www.ziprecruiter.com/Salaries/Headache-Specialist-Salary (accessed 2025–26). Treat as unreliable. ↩

  19. Cross-specialty figures. Neurology ~33% women practicing and the all-physician share of 38.7%: AAMC, "Women are changing the face of medicine in America" (2022 data), https://www.aamc.org/news/women-are-changing-face-medicine-america, and AAMC, 2025 Key Findings (2024 data), https://www.aamc.org/data-reports/data/2025-key-findings. Neurology burnout ~44% (field-synthesis reporting often says ~48–55%): Medscape Physician Burnout & Depression Report 2024, n=9,226, fielded July–October 2023. That report is paywalled and returns HTTP 402, so the figure reaches this page through two independent relays that agree on the edition, the instrument and every row — Healthgrades Pro (https://resources.healthgrades.com/pro/the-most-and-least-burned-out-physicians-by-specialty) and Advisory Board (https://www.advisory.com/daily-briefing/2024/01/31/physician-burnout). Neurology's DO and IMG accessibility: NRMP, Results and Data: 2026 Main Residency Match, May 2026, Table 2, https://www.nrmp.org/wp-content/uploads/2026/05/Main_Match_Results_and_Data-2026.pdf. On URiM, no current race-and-ethnicity-by-specialty table is published anywhere; AAMC's 2025 Key Findings gives the aggregate only (5.3% Black or African American and 6.7% Hispanic or Latino of active physicians in 2024), so the "below-average" line is a directional read rather than a cited neurology figure. Would-choose-medicine-again: no current figure, by specialty or overall. Correction, 2026-08-13: this footnote and the Wellbeing section previously gave "~78% of physicians would choose medicine again (Medscape secondary)." No current Medscape report publishes that number. Nothing has been published broken out by specialty since about 2019, and the most recent traceable datapoint of any kind is 68% among physicians under 40, in Medscape's 2022 Young Physician Compensation Report, which has no specialty breakdown. No replacement number is asserted here. Corrected 2026-08-17: this footnote said the Medscape burnout figure reaches the page through "three independent relays" and then named two. Two are named and two exist; there is no AMA Organizational Biopsy link in this footnote to serve as a third, as there is in some other profiles carrying the same phrase. The count now matches the list. ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  20. AAN abstract — gender in UCNS Headache Medicine certification & leadership: 645 providers, 276 (~43%) women; ~59% of new certifications (2016–2018) women; women renew certification at 88.9% vs men 79.9% (p=.005); fellowship directors ~66% women (only UCNS subspecialty with a majority-women fellowship-director cohort; others 20–50%); department heads ~39% women, neurology chairs ~12% women, AHS board ~25% women. https://aan.com/msa/Public/Events/AbstractDetails/43889 (accessed 2026). ⟳ ↩ ↩2 ↩3 ↩4 ↩5

  21. MDedge Neurology, "How does gender bias affect the headache field?" — qualitative documentation of underrepresentation of women among conference speakers and editorial invitations and slower accrual of "headache expert" recognition, despite a female-skewing pipeline. https://www.mdedge.com/neurology/article/204581/headache-migraine/how-does-gender-bias-affect-headache-field (accessed 2026). ↩

  22. Parent-field DO and IMG shares. NRMP, Results and Data: 2026 Main Residency Match, May 2026, Table 2, https://www.nrmp.org/wp-content/uploads/2026/05/Main_Match_Results_and_Data-2026.pdf — neurology offered 1,003 PGY-1 positions and filled 999, taking 583 US MD seniors, 4 MD graduates, 181 DO seniors, 7 DO graduates, 49 US IMGs and 175 non-US IMGs. On the positions-filled denominator that is 18.8% DO (188 of 999) and 22.4% IMG (224 of 999), with the internal IMG split 4.9% US-IMG and 17.5% non-US IMG. The same table's all-PGY-1 totals row gives 21.5% DO and 25.2% IMG of 38,354 filled positions, which is the baseline the FLI section compares against. Swept 2026-08-17: the dashboard, the demographics section and the FLI section carried ~16.5% DO and ~29% IMG from the 2025 report, and the pair was internally inconsistent as well as a cycle old — 16.5% was DO seniors alone over positions offered (154 of 932) while ~29% counted both IMG types. On one denominator the two cycles read DO 17.0% → 18.8% and IMG 29.1% → 22.4%. The FLI section's "one of the more DO/IMG-accessible specialties" went with the number, because neurology sits slightly below the all-PGY-1 rate on both axes. Value swept: 18.8% DO and 22.4% IMG, denominator positions filled, source NRMP Main Match 2026 Table 2. ⟳ ↩ ↩2 ↩3

  23. Miles for Migraine, "What is a Headache Fellow or Headache Specialist?" — a headache specialist is typically a neurologist who completed an extra UCNS-accredited fellowship year focused on headache/facial pain; underscores how few exist relative to need. https://www.milesformigraine.org/headache-fellow-headache-specialist/ (accessed 2026). ↩

  24. KevinMD, "How pain management solves a refractory headache" — pain-medicine commentary reflecting the field's therapeutic-optimism-meets-complex-chronic-pain identity and the multidisciplinary, procedure-plus-medication approach. https://kevinmd.com/2026/04/how-pain-management-solves-a-refractory-headache.html (2026). ↩

Researched with AI assistance and reviewed by hand. How this site is made